To date, medical management of PXE is mostly symptomatic (intraocular anti-VEGF treatment; primary and secondary cardiovascular prevention) as no curative treatment options are available yet, warranting further research into the pathogenic mechanisms of this disorder. This evidence concerns the gene VEGFA and Pseudoxanthoma elasticum.